Catalent Acquires Paragon Bioservices for $1.2 Billion
May 20, 2019
Catalent, Inc. completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing partner for gene therapies, expanding Catalent’s biologics and gene therapy capabilities. Paragon’s Baltimore-area facilities and ~380 employees will join Catalent’s global biologics platform, while Catalent secured financing including incremental term loans and a convertible preferred issuance to Leonard Green & Partners to support the transaction.
- Buyers
- Catalent, Inc.
- Targets
- Paragon Bioservices, Inc.
- Industry
- Biotechnology
- Location
- Maryland, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Elevance Health Acquires Paragon Healthcare
March 11, 2024
Healthcare Services
Elevance Health has closed its acquisition of Plano, Texas–based Paragon Healthcare, an infusion services and drug therapy provider operating more than 40 ambulatory infusion centers and serving over 35,000 patients. Paragon will operate under Elevance’s CarelonRx pharmacy services segment to expand access to specialty medications and scale infusion capabilities; financial terms were not disclosed (Axios reported the purchase may exceed $1 billion).
-
Aptean Acquires Paragon Software Systems
March 5, 2020
Software
Aptean, a global provider of industry-specific enterprise software, has acquired UK-based Paragon Software Systems, a specialist in transportation management, routing and scheduling solutions. The deal expands Aptean’s logistics and route-optimization capabilities and furthers its presence in the European market, adding Paragon’s installed base and customers in food & beverage, retail, distribution and pharmaceutical sectors.
-
Catalent Acquires Delphi Genetics to Add Plasmid DNA Capabilities
February 23, 2021
Biotechnology
Catalent has agreed to acquire 100% of Delphi Genetics, a Belgium-based plasmid DNA (pDNA) CDMO, and will integrate Delphi's pDNA development and cGMP manufacturing capabilities into its Cell & Gene Therapy business. The deal also supports Catalent's launch of pDNA services at its Rockville, Maryland facility, expanding integrated pDNA supply across Europe and the U.S.
-
Quantum Lifecycle Partners Acquires Paragon Bay Group
January 11, 2024
Environmental Services
Quantum Lifecycle Partners LP has acquired Paragon Bay Group Inc., a North Bay, Ontario specialist in testing, in‑warranty repair, asset recovery and forward/reverse logistics for electronics OEMs. Sixty Paragon Bay employees join Quantum as the deal expands Quantum's repair, 3PL logistics and IT device maintenance capabilities across Canada.
-
Merck Acquires Pandion Therapeutics
February 25, 2021
Biotechnology
Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.
-
Novo Holdings Acquires Catalent for $16.5 Billion
December 18, 2024
Healthcare Services
Novo Holdings has completed its previously announced all-cash acquisition of Catalent, Inc. for an enterprise value of approximately $16.5 billion, with Catalent stockholders receiving $63.50 per share. Shortly after closing, Novo Nordisk will acquire three Catalent fill-finish sites (Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium) and related assets from Novo Holdings.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.